# A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

Source: https://onco.cc/trials/nct04939610/  
OnCo record `nct04939610` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FAP-2286 (177Lu / 68Ga) in advanced solid tumours, run by Novartis Pharmaceuticals, now recruiting.

## Summary

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04939610 by Novartis Pharmaceuticals, with 222 participants planned, started 2021-07-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: 68Ga-FAP-2286 and 177Lu-FAP-2286.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04939610
- Phase: 1/2
- Setting: LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 222

## Sources

- ClinicalTrials.gov NCT04939610: https://clinicaltrials.gov/study/NCT04939610

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [FAP-2286 (177Lu / 68Ga)](https://onco.cc/drugs/fap-2286/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct04939610.json